Kelvyn Cullimore on Recent Pharmaceutical Legislation and Its Impact on Drug Pricing

In a recent insightful discussion hosted by PoliticIt, Kelvyn Cullimore, President and CEO of BioUtah, shared his expert perspective on the evolving landscape of pharmaceutical legislation, focusing particularly on the Trump administration’s proposed policies like the “most favored nation” clause and the so-called “pill penalty.” With over three decades of experience in the MedTech industry, and a deep understanding of both the policy and business sides of healthcare innovation, Cullimore offers a nuanced view on drug pricing, research and development, and the complex healthcare market in the United States compared to other countries.

This article distills and expands upon those critical points, exploring the background of these legislative efforts, their implications for pharmaceutical companies, patients, and the healthcare system, and possible paths forward for policymakers looking to balance innovation with affordability.

Understanding the “Pill Penalty” and Its Legislative Journey

One of the key topics Cullimore revisited is the “pill penalty,” a term that has gained attention due to disparities in patent protection periods for different types of drugs. To recap, the “pill penalty” refers to a provision stemming from the Inflation Reduction Act that creates unequal timelines for price negotiation eligibility based on the drug’s molecular type.

Specifically, large molecule drugs—often biologics administered via injection or infusion—are granted 13 years of protection before government negotiation on pricing can begin. In contrast, small molecule drugs, typically oral pills, only receive 9 years of protection. This discrepancy, Cullimore explains, has been seen as unfair, as all drugs arguably should have equal patent protection to encourage innovation and development.

PoliticIt Radio – BioDesert Highway

Though the pill penalty concept had bipartisan support and was championed by President Trump, it did not make it into the comprehensive legislative package often referred to as the “big beautiful bill.” Cullimore notes that while it has been temporarily sidelined, it is expected to resurface in some form, given its broad backing across the political spectrum.

The pill penalty debate highlights the intricate balance lawmakers must strike between incentivizing pharmaceutical innovation and controlling drug prices. It underscores the challenges of crafting legislation that addresses complex scientific and economic realities without unintended consequences.

The “Most Favored Nation” Clause: A Controversial Approach to Drug Pricing

Stealing much of the spotlight recently is the Trump administration’s push for the “most favored nation” (MFN) clause in pharmaceutical pricing. Issued as an executive order on May 12th, the MFN policy seeks to ensure that the United States pays no more for certain drugs than the lowest prices paid by a select group of other developed countries.

Cullimore explains the rationale: the U.S. shoulders a disproportionate share of the financial burden for drug research and development. This results in American consumers and taxpayers paying higher prices while other countries benefit from lower negotiated prices without contributing equally to innovation costs. The MFN clause is an attempt to “shake things up” and compel foreign nations to share more of this burden.

However, the method of achieving this goal—tying U.S. prices to the average prices in a coalition of five countries—amounts to government-imposed price controls, which Cullimore warns could have severe consequences. He draws a parallel to President Trump’s criticisms of NATO allies for not meeting their military spending commitments, highlighting a consistent theme of demanding fairness and shared responsibility.

Why Do Other Countries Pay Less?

The crux of the MFN debate lies in the fundamental differences in healthcare systems between the United States and many other developed nations. While the U.S. operates largely on a free-market model, many countries with lower drug prices utilize socialized or government-controlled healthcare systems.

In these socialist or single-payer systems, governments negotiate directly with pharmaceutical companies to set drug prices, often enforcing strict price caps. As a result, prices for the same drugs can be significantly lower abroad. Cullimore gives the example of a drug costing $100 in the U.S. but only $30 in Europe. This difference is not due to the intrinsic value of the drug but due to government negotiation and regulation.

Moreover, these foreign systems often decide which drugs to cover based on cost-effectiveness, using metrics such as quality-adjusted life years (QALYs). If a drug does not meet their threshold for extending life or quality of life sufficiently, it may not be covered or purchased, regardless of its availability elsewhere.

This approach, while effective in controlling costs, raises ethical concerns about patient access to potentially life-saving treatments. Cullimore highlights stark statistics on new cancer drug availability between 2011 and 2019: 96% of these drugs were available in the U.S., compared to only 71% in the UK, 59% in Japan, and a mere 29% in New Zealand.

These figures underscore that while Americans pay more, they also have access to a broader range of innovative medicines. In contrast, socialized healthcare models may restrict access to some new treatments due to cost considerations.

The Moral and Market Dilemmas for Drug Companies

Pharmaceutical companies face a difficult moral and financial balancing act. On one hand, they want to make their drugs available globally to improve patient outcomes. On the other hand, selling drugs at prices that do not cover development and manufacturing costs threatens their ability to invest in future innovations.

In some cases, companies may choose not to sell a drug in a country if the price offered is too low, or countries may refuse to purchase drugs at higher prices. This dynamic can lead to uneven global availability, with patients in some countries lacking access to new therapies.

Cullimore points out that the MFN clause, by enforcing U.S. prices to align with those lower foreign prices, risks undermining the entire ecosystem that funds research and development (R&D). If companies cannot recoup their investments in the U.S., where the majority of R&D occurs, the pipeline of new drugs could dry up.

Breaking Down the Complexity of Drug Pricing in the United States

While it is easy to point fingers at “big pharma” for high drug prices, Cullimore emphasizes that the reality is far more complex. The U.S. healthcare system involves multiple intermediaries and layers of pricing that impact the final cost paid by consumers.

The Role of Pharmacy Benefit Managers (PBMs)

One significant factor in drug pricing is the role played by Pharmacy Benefit Managers (PBMs). These entities negotiate drug prices and rebates on behalf of insurance companies and employers. PBMs create formularies—lists of approved drugs—and manage which drugs are covered and at what tier.

Crucially, PBMs receive rebates from pharmaceutical companies that can be as high as 50% or more of the drug’s list price. However, these rebates primarily benefit the PBMs themselves rather than the pharmacies or consumers. In many cases, PBMs operate mail-order pharmacies and require patients to use these services, contributing to the decline of local community pharmacies.

When a patient pays $100 for a drug, Cullimore explains, only a fraction of that amount actually goes to the pharmaceutical company. The rest is divided among PBMs, wholesalers, pharmacies, and other intermediaries. This fragmented system inflates the apparent cost of drugs and obscures who truly benefits financially.

Comparing U.S. Drug Pricing to Foreign Systems

In contrast to the U.S., foreign countries often have a single buyer—the government or a national health service—that negotiates prices directly with drug companies. This consolidated purchasing power allows governments to demand lower prices without the complex rebate structures seen in the U.S.

Interestingly, Cullimore notes that some drugs may actually generate similar or even higher revenues for pharmaceutical companies abroad, despite the lower sticker prices. This is partly because the absence of PBMs and rebates means the net revenue per drug sold can be comparable.

This comparison highlights the importance of looking beyond list prices to understand the true economics of drug pricing.

Profitability and Investment in Pharmaceutical Companies

Another misconception Cullimore addresses is the assumption that all pharmaceutical companies are highly profitable. In reality, only about 10% of pharmaceutical companies are consistently profitable. The remaining 90% are often in the R&D phase, investing heavily in developing new drugs that may or may not succeed.

Successful drugs often come from smaller companies that, after reaching certain milestones, sell their products or intellectual property to larger, profitable firms that have the resources to bring them to market.

This high-risk, high-reward model requires substantial capital investment, with many failed projects subsidized by the successes. It underscores why sustained investment is critical for innovation and why sudden price controls could disrupt this delicate balance.

Potential Solutions Beyond Price Controls

Given the complexity of the pharmaceutical market and the risks associated with blunt price control measures like the MFN clause, Cullimore advocates for alternative approaches to managing drug costs.

Simplifying the System and Increasing Transparency

One of the main challenges is the complexity of the U.S. drug distribution and payment system. Simplifying this system and increasing transparency around pricing and rebates could help identify inefficiencies and reduce unnecessary costs.

For example, legislation aimed at greater transparency of PBM practices could shine a light on rebate flows and pricing negotiations. While efforts in some states, including Utah, have faced hurdles, there is broad agreement that more openness is needed.

Nonprofit Manufacturing Initiatives

Cullimore highlights the efforts of Civica Rx, a nonprofit drug manufacturer based in Utah and supported by Intermountain Health. Civica Rx focuses on producing generic drugs that are in short supply and aims to provide affordable alternatives without the profit pressures faced by traditional pharmaceutical companies.

By manufacturing off-patent drugs and generics, Civica Rx has helped reduce prices on over 30 medications, demonstrating that market-driven solutions can offer meaningful relief to consumers without resorting to government price controls.

Encouraging Competition and Innovation

Competition is a natural driver of lower prices, particularly for generic drugs, which make up about 90% of prescriptions in the U.S. The presence of multiple generic manufacturers often results in prices that are comparable or even lower than those in foreign countries with price controls.

For the remaining 10% of high-profile, innovative drugs, sustaining investment in R&D is essential. Policymakers must carefully balance efforts to make these drugs affordable with the need to maintain incentives for innovation that ultimately saves and improves lives.

The High Stakes of Pharmaceutical Innovation

The pharmaceutical development process is expensive, lengthy, and fraught with risk. Cullimore points out that for every drug that succeeds, there are approximately ten that fail after significant investment.

Capital for drug development competes with other emerging technologies, such as artificial intelligence, which currently attract substantial funding. Reducing the financial returns on drug development through aggressive price controls could drive investors away from pharmaceuticals, slowing innovation.

Studies have suggested that if price controls similar to those proposed in the MFN clause had been implemented a decade ago, as many as 110 drugs might not have been developed. The long-term consequences would be fewer treatment options and diminished progress in combating diseases.

What the Public Should Understand About Drug Pricing

Cullimore urges the public to recognize the complexity of drug pricing and the unique features of the U.S. healthcare system. While the higher costs can be frustrating, they also reflect a system that provides access to a broader range of innovative treatments and superior healthcare services overall.

He stresses that the counter price paid by patients or insurers is not solely the pharmaceutical company’s revenue but is shared among many entities, including PBMs, wholesalers, and pharmacies. This understanding is crucial for informed debate and effective policymaking.

Transparency, simplification, and targeted reforms can help reduce costs without jeopardizing the future of drug innovation. The goal should be to preserve the incentives that drive lifesaving discoveries while making medicines more affordable and accessible.

Conclusion: Balancing Innovation, Access, and Affordability

The discussion with Kelvyn Cullimore highlights the multifaceted nature of pharmaceutical pricing and policy. Proposals like the “pill penalty” and “most favored nation” clause underscore the ongoing struggle to balance fair pricing, innovation incentives, and patient access.

While government intervention can help address imbalances, blunt tools such as price controls risk unintended consequences, including reduced drug availability and slower innovation. Instead, a combination of market-based solutions, increased transparency, nonprofit initiatives, and thoughtful legislation offers a promising path forward.

As stakeholders—policymakers, industry leaders, healthcare providers, and patients—navigate these complex issues, understanding the underlying economic and systemic factors is essential. Only with a comprehensive approach can we ensure a sustainable pharmaceutical ecosystem that delivers both breakthrough treatments and affordable care to all.

Kelvyn Cullimore’s insights provide a valuable guidepost in this ongoing conversation, emphasizing that while the challenges are significant, the stakes—improving and saving lives through medical innovation—make it imperative to get this balance right.

#politicit #utahelections #utpol